## Yusuke Furukawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5864973/publications.pdf

Version: 2024-02-01

76326 79698 6,277 170 40 73 citations h-index g-index papers 181 181 181 6949 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Fast in-vitro screening of FLT3-ITD inhibitors using silkworm-baculovirus protein expression system. PLoS ONE, 2022, 17, e0261699.	2.5	O
2	AMPâ€activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCRâ€ABL protein in CML cells. Cancer Science, 2021, 112, 194-204.	3.9	8
3	Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma. Leukemia, 2021, 35, 1506-1510.	7.2	3
4	Identification of characteristic proteins at late-stage erythroid differentiation in vitro. Human Cell, 2021, 34, 745-749.	2.7	2
5	mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3-and Blimp-1-mediated BCL-2 up-regulation. Haematologica, 2021, 106, 3008-3013.	3.5	6
6	Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma. Leukemia Research, 2021, 111, 106672.	0.8	1
7	K15 promoter-driven enforced expression of NKIRAS exhibits tumor suppressive activity against the development of DMBA/TPA-induced skin tumors. Scientific Reports, 2021, 11, 20658.	3.3	1
8	Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia, 2020, 34, 180-195.	7.2	47
9	Kinetics of cytokine receptor internalization under steady-state conditions affects growth of neighboring blood cells. Haematologica, 2020, 105, e325-e327.	3.5	1
10	Serum Endocrine Fibroblast Growth Factors as Potential Biomarkers for Chronic Kidney Disease and Various Metabolic Dysfunctions in Aged Patients. Internal Medicine, 2020, 59, 345-355.	0.7	14
11	Molecular basis of clonal evolution in multiple myeloma. International Journal of Hematology, 2020, 111, 496-511.	1.6	42
12	Splicing- and demethylase-independent functions of LSD1 in zebrafish primitive hematopoiesis. Scientific Reports, 2020, 10, 8521.	3.3	6
13	Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy. Leukemia, 2020, 34, 3088-3090.	7.2	7
14	Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor. Clinical Cancer Research, 2019, 25, 1601-1611.	7.0	17
15	Conversion of human fibroblasts into multipotent cells by cell-penetrating peptides. Biochemical and Biophysical Research Communications, 2019, 518, 134-140.	2.1	4
16	Lysine-specific demethylase 1 accelerates oncogenesis in p53 heterozygous mice via transcriptional repression of the residual Trp53 allele. Leukemia Research, 2019, 82, 29-32.	0.8	0
17	Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide. Cancer Research, 2018, 78, 1766-1778.	0.9	23
18	Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells. International Journal of Hematology, 2018, 107, 383-385.	1.6	0

#	Article	IF	Citations
19	Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells. Oncotarget, 2018, 9, 6450-6462.	1.8	14
20	Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines. PLoS ONE, 2017, 12, e0188680.	2.5	32
21	Multiple Myeloma: bench to bedside Denki Eido, 2017, 61, 93-96.	0.0	0
22	Histone deacetylases as novel therapeutic targets for refractory and relapsed multiple myeloma. Annals of Oncology, 2016, 27, vii31.	1.2	0
23	Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. International Journal of Hematology, 2016, 104, 281-292.	1.6	44
24	Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia. Molecular Cancer Therapeutics, 2016, 15, 94-105.	4.1	23
25	Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem/progenitor cells for malignant transformation. Experimental Hematology, 2015, 43, S63.	0.4	0
26	Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation. Blood, 2015, 125, 3731-3746.	1.4	47
27	Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5. Oncogene, 2015, 34, 314-322.	5.9	28
28	Molecular pathogenesis of multiple myeloma. International Journal of Clinical Oncology, 2015, 20, 413-422.	2.2	52
29	Soluble αKlotho as a candidate for the biomarker of aging. Biochemical and Biophysical Research Communications, 2015, 467, 1019-1025.	2.1	36
30	Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. Journal of Clinical Investigation, 2015, 125, 4375-4390.	8.2	85
31	Romidepsin Overcomes Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma Cells. Acta Haematologica, 2014, 132, 1-4.	1.4	7
32	Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia, 2014, 28, 1216-1226.	7.2	55
33	Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. International Journal of Hematology, 2014, 99, 726-736.	1.6	12
34	Purine Analog-Like Properties of Bendamustine Underlie Rapid Activation of DNA Damage Response and Synergistic Effects with Pyrimidine Analogues in Lymphoid Malignancies. PLoS ONE, 2014, 9, e90675.	2.5	25
35	The Novel Orally Active Proteasome Inhibitor K-7174 Exerts Anti-myeloma Activity in Vitro and in Vivo by Down-regulating the Expression of Class I Histone Deacetylases. Journal of Biological Chemistry, 2013, 288, 25593-25602.	3.4	23
36	Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma. Blood Cancer Journal, 2013, 3, e169-e169.	6.2	12

3

#	Article	IF	CITATIONS
37	BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia. Oncogene, 2013, 32, 1670-1681.	5.9	7
38	Homopiperazine Derivatives as a Novel Class of Proteasome Inhibitors with a Unique Mode of Proteasome Binding. PLoS ONE, 2013, 8, e60649.	2.5	14
39	Promoter methylation confers kidneyâ€specific expression of the <i>Klotho</i> gene. FASEB Journal, 2012, 26, 4264-4274.	0.5	75
40	Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8. EMBO Reports, 2012, 13, 142-149.	4.5	71
41	Reduced Histone H3K9 Acetylation of Clock Genes and Abnormal Glucose Metabolism in ob/ob Mice. Chronobiology International, 2012, 29, 982-993.	2.0	15
42	Latexin regulates the abundance of multiple cellular proteins in hematopoietic stem cells. Journal of Cellular Physiology, 2012, 227, 1138-1147.	4.1	20
43	BCR-ABL Regulates Death Receptor Expression for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Philadelphia Chromosome-Positive Leukemia. Blood, 2011, 118, 2740-2740.	1.4	0
44	Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19). Blood, 2010, 116, 962-970.	1.4	35
45	Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood, 2010, 116, 406-417.	1.4	121
46	HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia, 2010, 24, 1760-1768.	7.2	86
47	MSK1 activation in acute myeloid leukemia cells with FLT3 mutations. Leukemia, 2010, 24, 1087-1090.	7.2	16
48	Inactivation of the Retinoblastoma Protein by Mutant B-Raf in Malignant Melanoma. Nature Precedings, 2010, , .	0.1	0
49	Up-regulation of Survivin by the E2A-HLF Chimera Is Indispensable for the Survival of t(17;19)-positive Leukemia Cells. Journal of Biological Chemistry, 2010, 285, 1850-1860.	3.4	15
50	Vinculin Is Indispensable for Repopulation by Hematopoietic Stem Cells, Independent of Integrin Function. Journal of Biological Chemistry, 2010, 285, 31763-31773.	3.4	23
51	Expression Levels of Histone Deacetylases Determine the Cell Fate of Hematopoietic Progenitors. Journal of Biological Chemistry, 2009, 284, 30673-30683.	3.4	68
52	Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor $\hat{l}^2$ during steady-state growth of human mesangial cells. Kidney International, 2009, 75, 1173-1183.	5.2	21
53	Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro. Cancer Chemotherapy and Pharmacology, 2009, 64, 1129-1137.	2.3	4
54	Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes. British Journal of Dermatology, 2009, 161, 1232-1238.	1.5	21

#	Article	IF	CITATIONS
55	Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene, 2009, 28, 231-242.	5.9	171
56	Ablation of Neutral Cholesterol Ester Hydrolase 1 Accelerates Atherosclerosis. Cell Metabolism, 2009, 10, 219-228.	16.2	93
57	A novel missense mutation of ABCA1 in transmembrane $\hat{l}$ ±-helix in a Japanese patient with Tangier disease. Atherosclerosis, 2009, 206, 216-222.	0.8	8
58	Ectopic Expression and Role of RCAN1 in Myeloid Leukemia Cells Blood, 2009, 114, 1274-1274.	1.4	1
59	The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Anticancer Research, 2009, 29, 4589-96.	1.1	12
60	The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations. Oncogene, 2008, 27, 3102-3110.	5.9	27
61	Transcriptional Modulation Using HDACi Depsipeptide Promotes Immune Cell-Mediated Tumor Destruction of Murine B16 Melanoma. Journal of Investigative Dermatology, 2008, 128, 1506-1516.	0.7	84
62	Activation of Focal Adhesion Kinase in Detached Human Epidermal Cancer Cells and Their Long-term Survival Might be Associated with Cell Surface Expression of Laminin-5. Acta Dermato-Venereologica, 2008, 88, 100-107.	1.3	4
63	CD43, but not P-Selectin Glycoprotein Ligand-1, Functions as an E-Selectin Counter-Receptor in Human Pre-B–Cell Leukemia NALL-1. Cancer Research, 2008, 68, 790-799.	0.9	30
64	Cholesterol Reduction and Atherosclerosis Inhibition by Bezafibrate in Low-Density Lipoprotein Receptor Knockout Mice. Hypertension Research, 2008, 31, 999-1005.	2.7	7
65	Ras-mediated Up-regulation of Survivin Expression in Cytokine-dependent Murine Pro-B Lymphocytic Cells. Tohoku Journal of Experimental Medicine, 2008, 216, 25-34.	1.2	8
66	Bortezomib Overcomes Cell Adhesion-Mediated Drug Resistance Via Down-Regulation of VLA-4 Expression in Multiple Myeloma Blood, 2008, 112, 1634-1634.	1.4	2
67	Long-Term Results of Dose-Intensive Chemotherapy With G-CSF Support (TCC-NHL-91) for Advanced Intermediate-Grade Non-Hodgkin's Lymphoma: A Review of 59 Consecutive Cases Treated at a Single Institute. Oncology Research, 2008, 17, 137-149.	1.5	3
68	The expression of rad9 in head and neck cancer. Japanese Journal of Head and Neck Cancer, 2008, 34, 493-497.	0.1	0
69	Rad9 modulates the P21WAF1 pathway by direct association with p53. BMC Molecular Biology, 2007, 8, 37.	3.0	17
70	Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia, 2007, 21, 1005-1014.	7.2	53
71	E2F-6 Suppresses Growth-Associated Apoptosis of Human Hematopoietic Progenitor Cells by Counteracting Proapoptotic Activity of E2F-1. Stem Cells, 2007, 25, 2439-2447.	3.2	25
72	The regulation of Rad9 for therapy of head and neck cancer. Japanese Journal of Head and Neck Cancer, 2007, 33, 425-428.	0.1	0

#	Article	IF	Citations
73	Histone deacetylase inhibitor FK228 suppresses the Ras–MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene, 2006, 25, 512-524.	5.9	53
74	Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Investigational New Drugs, 2006, 25, 31-40.	2.6	46
75	Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by the Proteasome Inhibitor Bortezomib. Acta Haematologica, 2006, 115, 78-90.	1.4	48
76	Schedule-Dependent Interactions Between Pemetrexed and Cisplatin in Human Carcinoma Cell Lines In Vitro. Oncology Research, 2006, 16, 85-95.	1.5	16
77	THE ROLE OF RAD9 IN HEAD AND NECK CANCER. Japanese Journal of Head and Neck Cancer, 2006, 32, 417-422.	0.1	1
78	Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). Journal of Cellular Physiology, 2005, 203, 387-397.	4.1	42
79	Components of DNA Damage Checkpoint Pathway Regulate UV Exposure–Dependent Alterations of Gene Expression of FHIT and WWOX at Chromosome Fragile Sites. Molecular Cancer Research, 2005, 3, 130-138.	3.4	22
80	Methylation Silencing of the Apaf-1 Gene in Acute Leukemia. Molecular Cancer Research, 2005, 3, 325-334.	3.4	78
81	Frag1, a homolog of alternative replication factor C subunits, links replication stress surveillance with apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9655-9660.	7.1	23
82	Differential Roles of E-Type Cyclins During Transformation of Murine E2F-1–Deficient Cells. DNA and Cell Biology, 2005, 24, 173-179.	1.9	4
83	Pivotal Role of Survivin in Leukemogenesis by E2A-HLF Chimeric Transcription Factor Blood, 2005, 106, 2988-2988.	1.4	0
84	Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses. Current Gene Therapy, 2004, 4, 53-63.	2.0	13
85	Differentially expressed genes execute zinc-induced apoptosis in precancerous esophageal epithelium of zinc-deficient rats. Oncogene, 2004, 23, 8040-8048.	5.9	8
86	Alterations of Common Chromosome Fragile Sites in Hematopoietic Malignancies. International Journal of Hematology, 2004, 79, 238-242.	1.6	31
87	Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it. Molecular and Cellular Biochemistry, 2004, 258, 25-33.	3.1	18
88	Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro. Cancer Chemotherapy and Pharmacology, 2004, 54, 505-513.	2.3	14
89	Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells. Leukemia Research, 2004, 28, 623-629.	0.8	15
90	Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX. Biochemical and Biophysical Research Communications, 2004, 316, 1088-1093.	2.1	9

#	Article	IF	CITATIONS
91	Role of cyclins in cAMP inhibition of glomerular mesangial cell proliferation. Clinical Science, 2004, 107, 81-87.	4.3	7
92	Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. Anticancer Research, 2004, 24, 2705-12.	1.1	24
93	Identification of Novel p53-Binding Proteins by Biomolecular Interaction Analysis Combined with Tandem Mass Spectrometry. Molecular Biotechnology, 2003, 23, 203-212.	2.4	21
94	Alteration of the fragile histidine triad gene early in carcinogenesis: an update. Journal of Experimental Therapeutics and Oncology, 2003, 3, 291-296.	0.5	23
95	Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c. Oncogene, 2003, 22, 4074-4082.	5.9	30
96	A novel I-branching $\hat{I}^2$ -1,6-N-acetylglucosaminyltransferase involved in human blood group I antigen expression. Blood, 2003, 101, 2870-2876.	1.4	77
97	Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Molecular Cancer Research, 2003, 1, 940-7.	3.4	60
98	Apaf-1 Is a Mediator of E2F-1-induced Apoptosis. Journal of Biological Chemistry, 2002, 277, 39760-39768.	3.4	119
99	Differences in E2F subunit expression in quiescent and proliferating vascular smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H204-H212.	3.2	7
100	Phosphorylation of Fanconi Anemia Protein, FANCA, Is Regulated by Akt Kinase. Biochemical and Biophysical Research Communications, 2002, 291, 628-634.	2.1	15
101	Cell Cycle Control Genes and Hematopoietic Cell Differentiation. Leukemia and Lymphoma, 2002, 43, 225-231.	1.3	41
102	Hyperglycemia enhances VSMC proliferation with NF-κB activation by angiotensin II and E2F-1 augmentation by growth factors. Molecular and Cellular Endocrinology, 2002, 192, 75-84.	3.2	27
103	Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells. American Journal of Physiology - Cell Physiology, 2002, 283, C1715-C1721.	4.6	19
104	Vasoactive Intestinal Peptide and Cytokines Enhance Stem Cell Factor Production From Epidermal Keratinocytes DJM-1. Journal of Investigative Dermatology, 2002, 119, 1183-1188.	0.7	11
105	Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. Leukemia, 2002, 16, 1808-1817.	7.2	23
106	Direct Transcriptional Activation of Human Caspase-1 by Tumor Suppressor p53. Journal of Biological Chemistry, 2001, 276, 10585-10588.	3.4	80
107	In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 2001, 97, 1999-2007.	1.4	248
108	Vasoactive Intestinal Peptide Regulates its Receptor Expression and Functions of Human Keratinocytes via Type I Vasoactive Intestinal Peptide Receptors. Journal of Investigative Dermatology, 2001, 116, 743-749.	0.7	39

7

#	Article	IF	CITATIONS
109	Stimulation of GATA-2 as a mechanism of hydrogen peroxide suppression in hypoxia-induced erythropoietin gene expression. Journal of Cellular Physiology, 2001, 186, 260-267.	4.1	28
110	Schedule-dependent Synergism and Antagonism between Raltitrexed ("Tomudexâ€) and Methotrexate in Human Colon Cancer Cell Linesin vitro. Japanese Journal of Cancer Research, 2001, 92, 74-82.	1.7	4
111	Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex. Human Molecular Genetics, 2001, 10, 2651-2660.	2.9	81
112	Downregulation of an Aim-1 Kinase Couples with Megakaryocytic Polyploidization of Human Hematopoietic Cells. Journal of Cell Biology, 2001, 152, 275-288.	5.2	58
113	Schedule-Dependent Interaction Between Raltitrexed and 5-Fluorouracil in Human Colon Cancer Cell Lines In Vitro. Oncology Research, 2001, 12, 137-148.	1.5	5
114	Regulation of macrophage-specific gene expression by degenerated lipoproteins. Electrophoresis, 2000, 21, 338-346.	2.4	4
115	Three-dimensional matrix suppresses E2F-controlled gene expression in glomerular mesangial cells. Kidney International, 2000, 57, 1581-1589.	5.2	7
116	Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation. British Journal of Haematology, 2000, 110, 663-673.	2.5	87
117	In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. Leukemia, 2000, 14, 379-388.	7.2	30
118	Transcriptional repressor E2F-6 regulates apoptosis of hematopoietic stem cells. Experimental Hematology, 2000, 28, 1504-1505.	0.4	8
119	A Simple Semisolid Subtraction Method Using Carbodiimide-Coated Microplates. Molecular Biotechnology, 2000, 15, 193-200.	2.4	3
120	Tyrosine kinase inhibitors reduce bcl-2 expression and induce apoptosis in androgen-dependent cells. American Journal of Physiology - Cell Physiology, 2000, 278, C66-C72.	4.6	19
121	Induction of Ubiquitin-Conjugating Enzyme by Aggregated Low Density Lipoprotein in Human Macrophages and Its Implications for Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 128-134.	2.4	45
122	Phosphorylation of Bcl-2 Protein by CDC2 Kinase during G2/M Phases and Its Role in Cell Cycle Regulation. Journal of Biological Chemistry, 2000, 275, 21661-21667.	3.4	101
123	Failure of cdc2 promoter activation and G2/M transition by ANG II and AVP in vascular smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H515-H523.	3.2	3
124	UDP-GlcNAc:GalÂ1->3GalNAc (GlcNAc to GalNAc) Â1->6N-acetylglucosaminyltransferase holds a key role on the control of CD15s expression in human pre-B lymphoid cell lines. Glycobiology, 1999, 9, 1-12.	2.5	9
125	Transcriptional repression of the E2F-1 gene by interferon-α is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes. Oncogene, 1999, 18, 2003-2014.	5.9	43
126	Interferon-α repressed telomerase along with G1-accumulation of Daudi cells. Cancer Letters, 1999, 142, 23-30.	7.2	21

#	Article	IF	CITATIONS
127	Defective binding of IRFs to the initiator element of interleukin- $1\hat{l}^2$ -converting enzyme (ICE) promoter in an interferon-resistant Daudi subline. FEBS Letters, 1999, 450, 263-267.	2.8	14
128	Simultaneous core 2 $\hat{1}^21\hat{a}^{\dagger}$ '6N-acetylglucosaminyltransferase up-regulation and sialyl-LeXexpression during activation of human tonsillar B lymphocytes. FEBS Letters, 1999, 463, 125-128.	2.8	9
129	Single Glycosyltransferase, Core 2 $\hat{l}^2$ 1â†'6-N-acetylglucosaminyltransferase, Regulates Cell Surface Sialyl-Lex Expression Level in Human Pre-B Lymphocytic Leukemia Cell Line KM3 Treated with Phorbolester. Journal of Biological Chemistry, 1998, 273, 26779-26789.	3.4	33
130	Human monocyte-endothelial cell interaction induces platelet-derived growth factor expression. Cardiovascular Research, 1998, 37, 216-224.	3.8	41
131	A novel variant of acute myelomonocytic leukemia carrying $t(3;12)(q26;p13)$ with characteristics of 3q21q26 syndrome. International Journal of Hematology, 1998, 67, 361.	1.6	15
132	A Janus Kinase Inhibitor, JAB, Is an Interferon-γ–Inducible Gene and Confers Resistance to Interferons. Blood, 1998, 92, 1668-1676.	1.4	52
133	Cell cycle regulation of hematopoietic stem cells. Human Cell, 1998, 11, 81-92.	2.7	33
134	Modulation of E2F Activity Is Linked to Interferon-induced Growth Suppression of Hematopoietic Cells. Journal of Biological Chemistry, 1997, 272, 12406-12414.	3.4	39
135	The Expression of ST2 Gene in Helper T Cells and the Binding of ST2 Protein to Myeloma-Derived RPMI8226 Cells. Journal of Biochemistry, 1997, 121, 95-103.	1.7	94
136	Rapid internalization of exogenous ganglioside GM3 and its metabolism to ceramide in human myelogenous leukemia HL-60 cells compared with control ganglioside GM1. FEBS Letters, 1997, 400, 350-354.	2.8	8
137	Regulatory effects of aggregated LDL on apoptosis during foam cell formation of human peripheral blood monocytes. FEBS Letters, 1997, 409, 177-182.	2.8	16
138	Polyploidization and Functional Maturation Are Two Distinct Processes During Megakaryocytic Differentiation: Involvement of Cyclin-Dependent Kinase Inhibitor p21 in Polyploidization. Blood, 1997, 89, 3980-3990.	1.4	71
139	Cell-Cycle–Dependent Regulation of Erythropoietin Receptor Gene. Blood, 1997, 89, 1182-1188.	1.4	17
140	A LONG-TERMSURVIVAL CASE OF HEPATIC METASTASIS OF RECTAL CARCINOID. The Journal of the Japanese Practical Surgeon Society, 1997, 58, 1079-1083.	0.0	0
141	Cell cycle control during hematopoietic cell differentiation. Human Cell, 1997, 10, 159-64.	2.7	18
142	Interleukin-3-associated ganglioside GD1a is induced independently of normal interleukin-3 receptor in murine myelogenous leukaemia NFS60 cells transfected with the interleukin-3 gene. Glycoconjugate Journal, 1996, 13, 255-261.	2.7	6
143	Transcriptional Activation of the cdc2 Gene Is Associated with Fas-induced Apoptosis of Human Hematopoietic Cells. Journal of Biological Chemistry, 1996, 271, 28469-28477.	3.4	59
144	Herbimycin A down-regulates messages of cyclin D1 and c-myc during erythroid differentiation of K562 cells. International Journal of Hematology, 1996, 65, 31.	1.6	14

#	Article	IF	Citations
145	Human Monocyte–Endothelial Cell Interaction Induces Synthesis of Granulocyte-Macrophage Colony-Stimulating Factor. Circulation, 1996, 93, 1185-1193.	1.6	61
146	Tenascin-X expression in tumor cells and fibroblasts: glucocorticoids as negative regulators in fibroblasts. Journal of Cell Science, 1996, 109, 2069-2077.	2.0	29
147	Over-expression and amplification of the CDC2 gene in leukaemia cells. British Journal of Haematology, 1995, 90, 94-99.	2.5	8
148	Regulation of EGF-induced tenascin-C by steroids in tenascin-C-non-producing human carcinoma cells. International Journal of Cancer, 1995, 63, 720-725.	5.1	9
149	Apoptosis during HLâ€60 cell differentiation is closely related to a GO/G1 cell cycle arrest. Journal of Cellular Physiology, 1995, 164, 74-84.	4.1	51
150	Tenascin-C induction by the diffusible factor epidermal growth factor in stromal-epithelial interactions. Journal of Cellular Physiology, 1995, 165, 18-29.	4.1	20
151	Preferential Production of Interleukin- $1\hat{l}^2$ over Interleukin-1 Receptor Antagonist Contributes to Proliferation and Suppression of Apoptosis in Leukemic Cells. Japanese Journal of Cancer Research, 1995, 86, 208-216.	1.7	19
152	Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: A pilot study. Leukemia Research, 1995, 19, 899-903.	0.8	6
153	Expression of Differentiation-Related Phenotypes and Apoptosis Are Independently Regulated during Myeloid Cell Differentiation1. Journal of Biochemistry, 1995, 117, 77-84.	1.7	25
154	Biosynthesis of the So-Called "a" and "Asialo" Pathway Glycosphingolipids Is Differentially Regulated in Murine Myelogenous Leukemia NFS60 Cells. Biochemical and Biophysical Research Communications, 1995, 217, 733-740.	2.1	1
155	Tenascin-C Induction in Whitlock-Witte Culture: A Relevant Role of the Thiol Moiety in Lymphoid-Lineage Differentiation. Experimental Cell Research, 1995, 217, 395-403.	2.6	9
156	The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 1795-1798.	7.1	227
157	Treatment of myeloid leukemic cells with the phosphatase inhibitor okadaic acid induces cell cycle arrest at either G1/S or G2/M depending on dose. Journal of Cellular Physiology, 1992, 150, 484-492.	4.1	94
158	Interleukin 1 production by monocytic leukemia cells and its possible role in coagulation abnormalities. Leukemia Research, 1991, 15, 1133-1137.	0.8	6
159	Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. Oncogene, 1991, 6, 1343-6.	5.9	27
160	Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2770-2774.	7.1	137
161	cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science, 1990, 250, 805-808.	12.6	216
162	Antileukemic effect of nitrous oxide in a patient with chronic myelogenous leukemia. American Journal of Hematology, 1989, 30, 114-114.	4.1	6

#	Article	IF	CITATIONS
163	The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell, 1989, 58, 1085-1095.	28.9	942
164	Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. Journal of Immunology, 1989, 143, 3543-7.	0.8	37
165	Cytomegalovirus Gastritis as an Initial Manifestation of a Patient with Adult T-Cell Leukemia. Acta Haematologica, 1988, 80, 216-218.	1.4	16
166	Interleukin-1 derived from human monocytic leukemia cell line JOSK-I acts as an autocrine growth factor. Biochemical and Biophysical Research Communications, 1987, 147, 39-46.	2.1	8
167	Interleukin-1 producing ability of leukaemia cells and its relationship to morphological diagnosis. British Journal of Haematology, 1987, 65, 11-15.	2.5	28
168	Myeloid and erythroid lineage expression of haemopoietic progenitors derived from an abnormal clone in erythroleukaemia. British Journal of Haematology, 1986, 64, 647-656.	2.5	8
169	A case of cytophagic histiocytic panniculitis. Japanese Journal of Clinical Immunology, 1986, 9, 58-64.	0.0	1
	Establishment and characterization of four human monocytoid leukemia cell lines (IOSK-L-S-M and) Ti FTOo0 0	∩ rgRT /∩	werlock 10 Tf

Establishment and characterization of four human monocytoid leukemia cell lines (JOSK-I, -S, -M and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 0.9 33 interleukin 1. Cancer Research, 1986, 46, 3067-74.